MedTrace Logo

Efficacy of Lapaquistat Acetate on Blood Cholesterol Levels in Treating Subjects With Hypercholesterolemia

NCT00532558 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 657

Last updated 2012-05-24

No results posted yet for this study

Summary

The purpose of the study is to determine the reduction of LDL-cholesterol level after treatment with 50 mg per day of lapaquistat acetate once daily (QD).

Conditions

Interventions

DRUG

Lapaquistat acetate

Lapaquistat acetate 50 mg, tablets, orally, once daily for up to 12 weeks.

DRUG

Placebo

Lapaquistat acetate placebo-matching tablets, orally, once daily for up to 12 weeks.

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2008-05-31
Completion
2008-05-31

Countries

  • Estonia
  • Hungary
  • Israel
  • Latvia
  • Netherlands
  • Norway
  • Russia
  • Slovakia
  • Spain
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00532558 on ClinicalTrials.gov